Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Phytother Res ; 31(9): 1441-1448, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28766866

RESUMEN

The oral bioavailability of diltiazem is very low due to rapid first pass metabolism in liver and intestine. The purpose of the study was to investigate the effect of gallic acid and ellagic acid on intestinal transport and oral bioavailability of diltiazem in rats. The intestinal transport and permeability of diltiazem was evaluated by in vitro non-everted sac method and in situ single pass intestinal perfusion study. The oral pharmacokinetics was evaluated by conducting oral bioavailability study. The intestinal transport and apparent permeability of diltiazem were significantly enhanced in duodenum, jejunum, and ileum of gallic and ellagic acid-treated groups. The effective permeability of diltiazem was significantly enhanced in ileum part of gallic and ellagic acid-treated groups. When compared with control group, the presence of these two phytochemicals significantly enhanced the area under plasma concentration-time curve and the peak plasma concentration of diltiazem (Cmax ). Gallic acid and ellagic acid significantly increased the bioavailability of diltiazem due to the inhibition of both CYP3A-mediated metabolism and P-glycoprotein-mediated efflux in the intestine and/or liver. Based on these results, the clinical experiments are warranted for the confirmation to reduce the dose of diltiazem when concomitantly administered with these phytochemicals. Copyright © 2017 John Wiley & Sons, Ltd.


Asunto(s)
Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Citocromo P-450 CYP3A/metabolismo , Diltiazem/farmacocinética , Ácido Elágico/farmacología , Ácido Gálico/farmacología , Administración Oral , Animales , Disponibilidad Biológica , Diltiazem/administración & dosificación , Interacciones Farmacológicas , Absorción Intestinal , Mucosa Intestinal/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Ratas Wistar
2.
J Pharm Pharm Sci ; 20: 28-37, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28459658

RESUMEN

PURPOSE: Domperidone is a commonly used antiemetic drug. The oral bioavailability of domperidone is very low due to its rapid first pass metabolism in the intestine and liver. Piperine, the main alkaloid present in black pepper has been reported to show inhibitory effects on Cytochrome P-450 (CYP-450) enzymes and P-glycoprotein (P-gp). In the present study we investigated the effect of piperine pretreatment on the intestinal transport and oral bioavailability of domperidone in male Wistar rats. METHODS: The intestinal transport of domperidone was evaluated by an in-vitro non-everted sac method and in-situ single pass intestinal perfusion (SPIP) study. The oral pharmacokinetics of domperidone was evaluated by conducting oral bioavailability study in rats. RESULTS: A statistically significant improvement in apparent permeability (Papp) was observed in rats pretreated with piperine compared to the respective control group. The effective permeability (Peff) of domperidone was increased in the ileum of the piperine treated group. Following pretreatment with piperine, the peak plasma concentration (Cmax) and area under the concentration- time curve (AUC) were significantly increased. A significant decrease in time to reach maximum plasma concentration (Tmax), clearance and elimination rate constant (Kel) was observed in rats pretreated with piperine. CONCLUSIONS: Piperine enhanced the oral bioavailability of domperidone by inhibiting CYP3A1 and P-gp in rats. This observation suggests the possibility that the combination of piperine with other CYP3A4 and P-gp dual substrates may also improve bioavailability. Further clinical studies are recommended to verify this drug interaction in human volunteers and patients. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Alcaloides/farmacocinética , Benzodioxoles/farmacocinética , Citocromo P-450 CYP3A/metabolismo , Domperidona/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Piperidinas/farmacocinética , Alcamidas Poliinsaturadas/farmacocinética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Administración Oral , Alcaloides/administración & dosificación , Alcaloides/farmacología , Animales , Benzodioxoles/administración & dosificación , Benzodioxoles/farmacología , Disponibilidad Biológica , Domperidona/administración & dosificación , Domperidona/farmacología , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Masculino , Piperidinas/administración & dosificación , Piperidinas/farmacología , Alcamidas Poliinsaturadas/administración & dosificación , Alcamidas Poliinsaturadas/farmacología , Ratas , Ratas Wistar
3.
Drug Metab Pers Ther ; 31(4): 229-234, 2016 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-27875319

RESUMEN

BACKGROUND: Cytochrome P450-2D6 (CYP2D6), a member of the CYP450 mixed function oxidase system, is an important CYP isoform with regard to herbal-drug interactions and is responsible for the metabolism of nearly 25% of drugs. Until now, studies on the effects of various phytochemicals on CYP2D6 activity in vivo have been very rare. Gallic acid and ellagic acid are natural polyphenols which are widely distributed in fruits and medicinal plants. In the present study, the effects of gallic acid and ellagic acid pretreatment on intestinal transport and oral bioavailability of metoprolol were investigated. METHODS: The intestinal transport of metoprolol was assessed by conducting an in situ single pass intestinal perfusion (SPIP) study. The bioavailability study was conducted to evaluate the pharmacokinetic parameters of orally administered metoprolol in rats. RESULTS: After pretreatment with gallic acid and ellagic acid, no significant change in effective permeability of metoprolol was observed at the ileum part of rat intestine. A significant improvement in the peak plasma concentration (Cmax) and area under the serum concentration-time profile (AUC) and decrease in clearance were observed in rats pretreated with gallic acid and ellagic acid. CONCLUSIONS: Gallic acid and ellagic acid significantly enhanced the oral bioavailability of metoprolol by inhibiting CYP2D6-mediated metabolism in the rat liver. Hence, adverse herbal-drug interactions may result with concomitant ingestion of gallic acid and ellagic acid supplements and drugs that are CYP2D6 substrates. The clinical assessment of these interactions should be further investigated in human volunteers.


Asunto(s)
Inhibidores del Citocromo P-450 CYP2D6/administración & dosificación , Inhibidores del Citocromo P-450 CYP2D6/farmacocinética , Citocromo P-450 CYP2D6/metabolismo , Ácido Elágico/farmacocinética , Ácido Gálico/farmacocinética , Hígado/metabolismo , Metoprolol/farmacocinética , Administración Oral , Animales , Disponibilidad Biológica , Relación Dosis-Respuesta a Droga , Ácido Elágico/administración & dosificación , Ácido Gálico/administración & dosificación , Hígado/enzimología , Masculino , Metoprolol/administración & dosificación , Microsomas Hepáticos/enzimología , Ratas , Ratas Wistar , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA